TC BioPharm's boasts a strong IP portfolio of patents covering manufacturing and commercialization of GD-T cell products and their modification via CAR-T. Currently The Company owns 6 granted patents and a further 45 patent applications in 6 families encompassing: allogeneic gamma-delta T cells; novel 'co-stimulatory' gamma-delta CAR-T cells intended to mitigate on-target, off-tumour toxicity and broaden the choice of therapeutic targets addressable by CAR-T therapies; novel CAR constructs tailored for use in gamma-delta T-cells; modified gamma-delta T-cells intended to maintain activity in the immune suppressive solid tumour microenvironment; and proprietary antigen binders,and have an exclusive license to an additional 1 family of 3 granted patent application and 11 patent applications in the area of 'co-stimulatory' gamma-delta CAR-T cells.
"Patent portfolios and Intellectual Property are a core component of any biotechnology company and a necessity when building a competitive advantage. We are extremely pleased with our strong portfolio of IP assets that we have assembled in the the co-stimulatory CAR-T Gamma Delta T-cell space," said Bryan Kobel , CEO of TC BioPharm. "These assets form the foundation for our ability to strengthen our product pipeline, and enhance our position as a leader in the field of Gamma Delta-T based immuno-oncology. Going forward we intend to continue to advance our global clinical development and commercialization strategy supported by our strong intellectual property estate."
The Company's IP also covers proprietary know how in the areas of gamma delta t-cell expansion, a core component to the Company's product. TCBP continues to expand it's patent portfolio and IP position, and anticipates filing further patent applications around its proprietary CAR-T platform.
“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful”
Warren Buffett
Recent TCBP News
- TCBP Announces Launch of Compassionate Use Program for TCB008 • PR Newswire (US) • 05/15/2024 12:30:00 PM
- TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds • PR Newswire (US) • 05/06/2024 05:01:00 PM
- TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies • PR Newswire (US) • 05/06/2024 12:30:00 PM
- TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies • PR Newswire (US) • 04/04/2024 12:32:00 PM
- TCBP Increasing Treatment Capacity with Expanded Manufacturing Process • PR Newswire (US) • 04/02/2024 12:30:00 PM
- TCBP Adjourns General Meeting Until a Later Date • PR Newswire (US) • 03/19/2024 12:30:00 PM
- TCBP Announces Exercise of Series D Warrants For Cash • PR Newswire (US) • 03/18/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 11:30:38 AM
- Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show" • PR Newswire (US) • 03/01/2024 01:30:00 PM
- /C O R R E C T I O N -- TC BioPharm/ • PR Newswire (US) • 02/27/2024 10:15:00 PM
- TCBP Announces Shareholder Update Call on March 5th 2024 • PR Newswire (US) • 02/27/2024 01:30:00 PM
- TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial • PR Newswire (US) • 02/22/2024 02:32:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/20/2024 11:05:14 AM
- TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe • PR Newswire (US) • 02/15/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 07:48:40 PM
- TCBP Provides Shareholder Update and Highlights Upcoming Milestones • PR Newswire (US) • 02/14/2024 01:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/09/2024 08:26:49 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/29/2024 02:16:48 PM
- TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show' • PR Newswire (US) • 01/29/2024 01:30:00 PM
- TC BioPharm to Present at the Sequire Investor Summit • PR Newswire (US) • 01/18/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 01:46:05 PM
- TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement • PR Newswire (US) • 01/04/2024 01:30:00 PM
- TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies • PR Newswire (US) • 01/03/2024 01:30:00 PM
- TC BioPharm Announces Closing of $3.5 Million Public Offering • PR Newswire (US) • 12/22/2023 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 10:14:09 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM